Loading
A phase 2 trial of Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell) in sarcomas, run by CNBG-Virogin Biotech (Shanghai) Ltd., now recruiting.
Clinical Study of VG161 in the Treatment of Advanced Bone and Soft Tissue Sarcoma is a phase 2 interventional study registered as NCT06126510 by CNBG-Virogin Biotech (Shanghai) Ltd., with 40 participants planned, started 2023-07-18 and due to reach its primary completion in 2025-07-17. Interventions recorded: Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/